May 23, 2020
New Late-Breaking Data at EAN Indicate Evobrutinib is the First BTK Inhibitor to Report Efficacy and Safety in MS Over 108 Weeks
Apr 27, 2020
Innovent Announces First Patient Dosed in a Pivotal Trial of Parsaclisib in Patients with Indolent Lymphoma in China
Apr 21, 2020
U.S. FDA Approves IMBRUVICA® (ibrutinib) Plus Rituximab for the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Apr 21, 2020
IMBRUVICA® (ibrutinib) Receives 11th FDA Approval
Apr 07, 2020
Ascentage Pharma Announces Approval for the Phase Ib/II Clinical Study of Bcl-2 Inhibitor APG-2575 for the Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in China
Jan 08, 2020
New Treatment Approved in Canada for Most Common Type of Leukemia
Dec 08, 2019
Lilly Presents Interim Clinical Data from LOXO-305 Dose Escalation Trial in B-Cell Leukemias and Lymphomas at the American Society Hematology Annual Meeting
Dec 07, 2019
More than Seven-Year Analysis of Early Treatment with IMBRUVICA® (ibrutinib) Monotherapy Showed Improved Progression-Free Survival in Patients with Mantle Cell Lymphoma (MCL) that Relapsed or Were Unresponsive to Prior Regimen
Dec 07, 2019
Extended Follow-up Phase 3 Data Underscore Sustained Efficacy and Safety of IMBRUVICA® (ibrutinib) in the Treatment of Chronic Lymphocytic Leukemia (CLL)
Nov 08, 2019
Janssen Announces Submission of Supplemental New Drug Application to U.S. FDA Seeking Approval of IMBRUVICA® (ibrutinib) in Combination with Rituximab for Previously Untreated Patients with Chronic Lymphocytic Leukemia
Nov 08, 2019
AbbVie Submits Supplemental New Drug Application to U.S. FDA For IMBRUVICA® (ibrutinib) in Combination with Rituximab for the Treatment of Previously Untreated, Younger Adults with Chronic Lymphocytic Leukemia
Nov 06, 2019
Eli Lilly and Company to Present Multiple Abstracts for LOXO-305 at ASH 2019
Oct 09, 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Oct 08, 2019
Health Canada approves CALQUENCE® (acalabrutinib) for adult patients with previously-treated mantle cell lymphoma (MCL)
Sep 10, 2019
EMD Serono Initiates Pivotal Phase III Program for Investigational Evobrutinib in Relapsing Multiple Sclerosis
Jul 08, 2019
Calquence (acalabrutinib; AstraZeneca/Acerta) Markets, 2017-2026: A Novel, Orally Available, Second-Generation Bruton's Tyrosine Kinase Inhibitor with Potential Antineoplastic Activity
Jul 08, 2019
Zanubrutinib (BeiGene) Drug Overview and Product Profiles 2017-2026
May 10, 2019
Positive Phase II Data Further Highlights Clinical Proof of Concept for Evobrutinib, First Oral Bruton's Tyrosine Kinase (BTK) Inhibitor to Report Positive Phase II Clinical Results in MS
Jan 07, 2019
Lilly Announces Agreement To Acquire Loxo Oncology
Nov 26, 2018
Two Posters on DB102 (Enzastaurin) Presented at the American Society of Hematology Annual Meeting